MIRM sees near-term clinical catalysts and LIVMARLI expansion efforts
TradingView News discussion points to a diversified rare-disease portfolio, strong commercial growth, regulatory progress for volixibat and brelovitug, and efforts to expand LIVMARLI’s reach.